TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01801540

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-arabinose - effect on glucose metabolism
Description: L-arabinose is mixed into the dough of the buns and cup cakes
Study: NCT02672527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04202042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological first aid
Description: PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual organisational intervention
Description: Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
Study: NCT02641340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously
Study: NCT03691532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated control (CON)
Description: Seated rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm cycle exercise (ACE)
Description: Arm cycling at a continuous power output

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
Study: NCT02641340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously
Study: NCT03555929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
Study: NCT01822743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic compression of pterygopalatine node
Study: NCT02641340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate IV
Description: Fentanyl Citrate 50 mcg, delivered intravenously
Study: NCT02627976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression vest, Thuasne
Description: Wearing a compression 4 days/weel with a minumum of 6 hours per day
Study: NCT01920672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Planned Activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Safety and Education Program
Study: NCT01297491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Study: NCT01805791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 1800 mg/day
Description: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
Study: NCT01822743

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham comparator
Study: NCT00525356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Talent Stent-Graft-System
Study: NCT01225302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: Low dose linifanib (once a day)
Study: NCT01805791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 2400 mg/day
Description: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
Study: NCT02942732

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
Study: NCT01225302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: High dose linifanib (once a day)
Study: NCT02942732

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
Study: NCT00000400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone [hPTH-(1-34)]
Description: 37 mcg once daily by self-administered sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone [hPTH-(1-34)]
Description: 37 mcg once daily by self-administered sc injection
Study: NCT01225302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on Day 1 of every 21-day cycle
Study: NCT01392937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: All-in-One Light multipurpose
Description: The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
Study: NCT00000400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: 70 mg/week by oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: 70 mg/week by oral route
Study: NCT02177071

Intervention type: DRUG
Group type: OTHER
Intervention: INFLIXIMAB

Intervention type: DRUG
Group type: OTHER
Intervention: AZATHIOPRINE

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Study: NCT01392937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquify care
Description: The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
Study: NCT03150212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856
Description: 2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
Study: NCT02177071

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study: NCT02864654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADRC injection
Description: 10 mL of autologous ADRC suspension will be injected intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study: NCT03667456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-rehabilitation by digital support
Description: Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
Study: NCT01015638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and BPO 5% gel
Description: Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Description: Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
Study: NCT03150212

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
Study: NCT00632359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg daily given for 12 months
Study: NCT03956238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
Study: NCT01987115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial manipulation
Description: Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
Study: NCT00254072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass
Description: The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass
Description: The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
Study: NCT04077359

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
Study: NCT04075175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S315
Description: Human monoclonal antibody against Diphtheria Toxin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (NaCl)
Description: Placebo 0.9% Sodium Chloride (NaCl)
Study: NCT00753519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
Study: NCT01794702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion).
Study: NCT01735812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IceSense3 system
Description: The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
Study: NCT03956238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
Study: NCT04059250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobio composite
Description: Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional composite
Description: traditional composite which has no bactericidal activities
Study: NCT03956238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition
Study: NCT00534599

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate XR
Description: oral
Study: NCT00479752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 (Oxaliplatin), Cetuximab
Description: Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 (Oxaliplatin), Cetuximab
Description: Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.
Study: NCT01802047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: milk expression with electric pump
Study: NCT04639440

Intervention type: OTHER
Intervention: Adipose tissue
Description: Adipose tissue sampling

Intervention type: OTHER
Intervention: Adipose tissue
Description: Adipose tissue sampling